La veille de la cybersécurité

Gibson recently spoke with McKinsey's Lydia The about how AI and machine learning can speed up drug discovery--and what it could mean for patients everywhere. An edited version of their conversation follows. Lydia The: You were part of several biotech firms before you cofounded Generate Biomedicines. Tell us about Generate's potential for revolutionizing medicine. Molly Gibson: Generate is focused on transforming drug discovery in the protein therapeutics space.